Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy.

Marco Di BattistaAlessandra Della RossaMarta Mosca

Published in: The Journal of rheumatology (2024)

We observed a sustained efficacy of selexipag on SSc digital vasculopathy during 1 year of administration. Our promising results encourage the design of a new randomized controlled trial to evaluate the effect of selexipag on SSc digital vasculopathy.

Keyphrases

systemic sclerosis
pulmonary arterial hypertension
randomized controlled trial
interstitial lung disease
pulmonary hypertension
study protocol
electronic health record
rheumatoid arthritis
systematic review
machine learning
idiopathic pulmonary fibrosis